Fungal infections caused by TRICHOSPORON that may become systemic especially in an IMMUNOCOMPROMISED HOST. Clinical manifestations range from superficial cutaneous infections to systemic lesions in multiple organs.
A mitosporic fungal genus causing opportunistic infections, endocarditis, fungemia, a hypersensitivity pneumonitis (see TRICHOSPORONOSIS) and white PIEDRA.
Mycoses are a group of diseases caused by fungal pathogens that can infect various tissues and organs, potentially leading to localized or systemic symptoms, depending on the immune status of the host.
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues.
Cyclic hexapeptides of proline-ornithine-threonine-proline-threonine-serine. The cyclization with a single non-peptide bond can lead them to be incorrectly called DEPSIPEPTIDES, but the echinocandins lack ester links. Antifungal activity is via inhibition of 1,3-beta-glucan synthase production of BETA-GLUCANS.
Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.
Deoxyribonucleic acid that makes up the genetic material of fungi.

Selection of resistant fungi in liver transplant recipients during use of newer antifungal agents -- a report of two cases. (1/12)

INTRODUCTION: Because invasive fungal infections cause significant morbidity and mortality in liver transplant recipients, the use of antifungal prophylaxis, and the early empirical use of antifungal agents, is widespread on liver transplant units. The new-generation azoles such as voriconazole and the echinocandins have been welcome additions to the antifungal armamentarium. These agents have become the leading options for prophylaxis in liver transplant units, despite the absence of strong data for their efficacy in this setting. CLINICAL PICTURE: We report two recipients of living-donor liver transplants who became infected/colonised with fungi resistant to an echinocandin and the azoles after exposure to these agents. One patient developed trichosporonosis while on caspofungin and the other became infected/ colonised with Candida glabrata that was resistant to voriconazole and posaconazole. CONCLUSION: We report these to highlight some of the consequences of using the newer antifungal agents.  (+info)

Three-locus identification, genotyping, and antifungal susceptibilities of medically important Trichosporon species from China. (2/12)

 (+info)

Current knowledge of Trichosporon spp. and Trichosporonosis. (3/12)

 (+info)

Disseminated trichosporonosis in a burn patient: meningitis and cerebral abscess due to Trichosporon asahii. (4/12)

 (+info)

Isolation and antifungal susceptibility testing of Trichosporon asahii in Ceara, Brazil. (5/12)

 (+info)

Trichosporon inkin, an unusual agent of fungal sinusitis: a report from south India. (6/12)

 (+info)

Breakthrough trichosporonosis in patients receiving echinocandins: case report and literature review. (7/12)

Trichosporon species now ranks as the second most common cause of disseminated yeast infections with a high mortality rate. Breakthrough trichosporonosis in patients receiving echinocandins therapy is being recognized recently. We present a case of breakthrough trichosporonosis with acute viral myocarditis while receiving caspofungin therapy. Trichosporon infection should be considered in patients, who have risk factors for invasive fungal infection and develop unexplained clinical manifestations of infection despite treatment with echinocandins.  (+info)

Development of a peptide nucleic acid probe to Trichosporon species and identification of trichosporonosis by use of in situ hybridization in formalin-fixed and paraffin-embedded (FFPE) sections. (8/12)

 (+info)

Trichosporonosis is a fungal infection caused by the organism Trichosporon spp., which are commonly found in the environment, particularly in soil and water. This infection primarily affects the skin and nails but can also cause invasive systemic disease, especially in immunocompromised individuals. The symptoms of trichosporonosis vary depending on the location and severity of the infection. Superficial infections may present as white plaques or pustules on the mucous membranes, while invasive infections can cause fever, chills, and organ dysfunction. Treatment typically involves antifungal medications, with the choice of drug depending on the severity and location of the infection.

Trichosporon is a genus of fungi that are commonly found in the environment, particularly in soil, water, and air. They are also part of the normal flora of the human skin and mucous membranes. Some species of Trichosporon can cause various types of infections, mainly in people with weakened immune systems. These infections can range from superficial (e.g., skin and nail) to systemic and invasive, affecting internal organs. The most common Trichosporon-related infection is white piedra, a superficial mycosis that affects the hair shafts.

In a medical context, Trichosporon refers specifically to these fungi with potential pathogenic properties. It's essential to distinguish between the general term "trichosporon" (referring to the genus) and "Trichosporon" as a medically relevant entity causing infections.

Mycoses are a group of diseases caused by fungal infections. These infections can affect various parts of the body, including the skin, nails, hair, lungs, and internal organs. The severity of mycoses can range from superficial, mild infections to systemic, life-threatening conditions, depending on the type of fungus and the immune status of the infected individual. Some common types of mycoses include candidiasis, dermatophytosis, histoplasmosis, coccidioidomycosis, and aspergillosis. Treatment typically involves antifungal medications, which can be topical or systemic, depending on the location and severity of the infection.

Antifungal agents are a type of medication used to treat and prevent fungal infections. These agents work by targeting and disrupting the growth of fungi, which include yeasts, molds, and other types of fungi that can cause illness in humans.

There are several different classes of antifungal agents, including:

1. Azoles: These agents work by inhibiting the synthesis of ergosterol, a key component of fungal cell membranes. Examples of azole antifungals include fluconazole, itraconazole, and voriconazole.
2. Echinocandins: These agents target the fungal cell wall, disrupting its synthesis and leading to fungal cell death. Examples of echinocandins include caspofungin, micafungin, and anidulafungin.
3. Polyenes: These agents bind to ergosterol in the fungal cell membrane, creating pores that lead to fungal cell death. Examples of polyene antifungals include amphotericin B and nystatin.
4. Allylamines: These agents inhibit squalene epoxidase, a key enzyme in ergosterol synthesis. Examples of allylamine antifungals include terbinafine and naftifine.
5. Griseofulvin: This agent disrupts fungal cell division by binding to tubulin, a protein involved in fungal cell mitosis.

Antifungal agents can be administered topically, orally, or intravenously, depending on the severity and location of the infection. It is important to use antifungal agents only as directed by a healthcare professional, as misuse or overuse can lead to resistance and make treatment more difficult.

Echinocandins are a class of antifungal medications that inhibit the synthesis of 1,3-β-D-glucan, a key component of the fungal cell wall. This results in osmotic instability and ultimately leads to fungal cell death. Echinocandins are commonly used to treat invasive fungal infections caused by Candida species and Aspergillus species. The three drugs in this class that are approved for use in humans are caspofungin, micafungin, and anidulafungin.

Here's a brief overview of each drug:

1. Caspofungin (Cancidas, Cancidas-W): This is the first echinocandin to be approved for use in humans. It is indicated for the treatment of invasive candidiasis, including candidemia, acute disseminated candidiasis, and other forms of Candida infections. Caspofungin is also approved for the prevention of Candida infections in patients undergoing hematopoietic stem cell transplantation.
2. Micafungin (Mycamine): This echinocandin is approved for the treatment of candidemia, esophageal candidiasis, and other forms of Candida infections. It is also used for the prevention of Candida infections in patients undergoing hematopoietic stem cell transplantation.
3. Anidulafungin (Eraxis): This echinocandin is approved for the treatment of esophageal candidiasis and candidemia, as well as other forms of Candida infections. It is also used for the prevention of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Echinocandins have a broad spectrum of activity against many fungal species, including those that are resistant to other classes of antifungal medications. They are generally well-tolerated and have a low incidence of drug interactions. However, they should be used with caution in patients with hepatic impairment, as their metabolism may be affected by liver dysfunction.

Amphotericin B is an antifungal medication used to treat serious and often life-threatening fungal infections. It works by binding to the ergosterol in the fungal cell membrane, creating pores that lead to the loss of essential cell components and ultimately cell death.

The medical definition of Amphotericin B is:

A polyene antifungal agent derived from Streptomyces nodosus, with a broad spectrum of activity against various fungi, including Candida, Aspergillus, Cryptococcus, and Histoplasma capsulatum. Amphotericin B is used to treat systemic fungal infections, such as histoplasmosis, cryptococcosis, candidiasis, and aspergillosis, among others. It may be administered intravenously or topically, depending on the formulation and the site of infection.

Adverse effects associated with Amphotericin B include infusion-related reactions (such as fever, chills, and hypotension), nephrotoxicity, electrolyte imbalances, and anemia. These side effects are often dose-dependent and may be managed through careful monitoring and adjustment of the dosing regimen.

Fungal DNA refers to the genetic material present in fungi, which are a group of eukaryotic organisms that include microorganisms such as yeasts and molds, as well as larger organisms like mushrooms. The DNA of fungi, like that of all living organisms, is made up of nucleotides that are arranged in a double helix structure.

Fungal DNA contains the genetic information necessary for the growth, development, and reproduction of fungi. This includes the instructions for making proteins, which are essential for the structure and function of cells, as well as other important molecules such as enzymes and nucleic acids.

Studying fungal DNA can provide valuable insights into the biology and evolution of fungi, as well as their potential uses in medicine, agriculture, and industry. For example, researchers have used genetic engineering techniques to modify the DNA of fungi to produce drugs, biofuels, and other useful products. Additionally, understanding the genetic makeup of pathogenic fungi can help scientists develop new strategies for preventing and treating fungal infections.

... is a systemic disease associated with fungi in the genus Trichosporon. It can appear in patients who are ... Marty FM, Barouch DH, Coakley EP, Baden LR (November 2003). "Disseminated trichosporonosis caused by Trichosporon loubieri". J ...
and Trichosporonosis". Clinical Microbiology Reviews. 24 (4): 682-700. doi:10.1128/CMR.00003-11. PMC 3194827. PMID 21976604. ... T. asteroides causes trichosporonosis, causing deep-seated, mucosa-associated, superficial, and systematic infections including ... Garg, Vaibhav; Jones, Elizabeth K.; Friedman, Ben J.; Lee, Jason B.; Yang, Sherry (2018). "Invasive trichosporonosis treated ... Azole antifungals are often used as a front-line therapy in trichosporonosis. Resistance to amphotericin, flucytosine, ...
Marty FM, Barouch DH, Coakley EP, Baden LR (2003). "Disseminated trichosporonosis caused by Trichosporon loubieri". Journal of ... Species said to be agents of trichosporonosis are T. asahii, T. asteroides, Cutaneotrichosporon cutaneum, Cutaneotrichosporon ... Trichosporon species can also cause severe opportunistic infections (trichosporonosis) in immunocompromised individuals. The ... Much more serious opportunistic infections, collectively called trichosporonosis, have been reported in immunocompromised ...
Trichosporonosis and Geotrichosis". JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 11 (5): 381-394. doi:10.1111/ddg ...
"Disseminated Trichosporonosis in a Burn Patient: Meningitis and Cerebral Abscess Due to Trichosporon asahii". Journal of ...
  • Trichosporonosis is a systemic disease associated with fungi in the genus Trichosporon. (wikipedia.org)
  • The fungus Trichosporon beigelii, which can produce skin lesions on the torso, face, and arms, causes trichosporonosis. (healthychildren.org)
  • Infecciones fúngicas causadas por TRICHOSPORON que pueden llegar a ser sistémicas especialmente en el HUÉSPED INMUNOCOMPROMETIDO. (bvsalud.org)
  • In a revision of almost 400 cases previously documented all over the world in patients with any underlying disease, the authors identified 287 cases of trichosporonosis and 99 cases of geotrichosis. (medscape.com)
  • conducted the largest retrospective multicenter study on invasive trichosporonosis and geotrichosis in Italian patients suffering from HMs over a 20-year period. (medscape.com)
  • Fungemia is the most common presentation of invasive trichosporonosis. (medscape.com)
  • on 33 cases of invasive trichosporonosis in HMs, levels of β- D -glucan were elevated in only half of the patients, and only a few patients exhibited increased levels prior to a positive blood culture. (medscape.com)
  • [ 34 , 35 ] A false-positive cryptococcal latex test may occur in patients with invasive trichosporonosis owing to the presence of a cell wall antigens cross-reacting with Cryptococcus neoformans capsular antigen. (medscape.com)
  • 7. Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazol. (nih.gov)
  • 14. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. (nih.gov)
  • The main case series of trichosporonosis published in literature have been reported in Table 2 . (medscape.com)

No images available that match "trichosporonosis"